With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...
"Soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials," said Mike Stewart, Founder and CEO of Soter Bio. "Partnering with Cellipont ...
HEFEI, ANHUI, CHINA, January 19, 2026 /EINPresswire.com/ — The global photovoltaic (PV) industry is entering a phase defined less by headline capacity additions and ...
Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results